Display options
Cite
Wikstrom J, Liu Y, Whatling C, et al. Diastolic dysfunction and impaired cardiac output reserve in dysmetabolic nonhuman primate with proteinuria. J Diabetes Complications. 2021;35(4):107881doi: 10.1016/j.jdiacomp.2021.107881.
Wikstrom, J., Liu, Y., Whatling, C., Gan, L. M., Konings, P., Mao, B., Zhang, C., Ji, Y., Xiao, Y. F., & Wang, Y. (2021). Diastolic dysfunction and impaired cardiac output reserve in dysmetabolic nonhuman primate with proteinuria. Journal of diabetes and its complications, 35(4), 107881. https://doi.org/10.1016/j.jdiacomp.2021.107881
Wikstrom, Johannes, et al. "Diastolic dysfunction and impaired cardiac output reserve in dysmetabolic nonhuman primate with proteinuria." Journal of diabetes and its complications vol. 35,4 (2021): 107881. doi: https://doi.org/10.1016/j.jdiacomp.2021.107881
Wikstrom J, Liu Y, Whatling C, Gan LM, Konings P, Mao B, Zhang C, Ji Y, Xiao YF, Wang Y. Diastolic dysfunction and impaired cardiac output reserve in dysmetabolic nonhuman primate with proteinuria. J Diabetes Complications. 2021 Apr;35(4):107881. doi: 10.1016/j.jdiacomp.2021.107881. Epub 2021 Feb 05. PMID: 33612386.
Copy Download .nbib Format: NLM
Share it on

J Diabetes Complications. 2021 Apr;35(4):107881. doi: 10.1016/j.jdiacomp.2021.107881. Epub 2021 Feb 05.

Diastolic dysfunction and impaired cardiac output reserve in dysmetabolic nonhuman primate with proteinuria.

Journal of diabetes and its complications

Johannes Wikstrom, Yongqiang Liu, Carl Whatling, Li-Ming Gan, Peter Konings, Binchen Mao, Chao Zhang, Yanqin Ji, Yong-Fu Xiao, Yixin Wang

Affiliations

  1. Bioscience, Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden. Electronic address: [email protected].
  2. Crown Bioscience Inc., 6 West Beijing Road, Taicang, Jiangsu, China.
  3. Translational Science and Experimental Medicine, Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  4. Early Clinical Development, Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  5. Quantitative Biology, Discovery Sciences, R&D, AstraZeneca, Gothenburg, Sweden.
  6. Crown Bioscience Inc., 6 West Beijing Road, Taicang, Jiangsu, China. Electronic address: [email protected].

PMID: 33612386 DOI: 10.1016/j.jdiacomp.2021.107881

Abstract

BACKGROUND: Cardiorenal complications are common in patients with dysmetabolism and diabetes. The present study aimed to examine if a nonhuman primate (NHP) model with spontaneously developed metabolic disorder and diabetes develops similar complications to humans, such as proteinuria and cardiac dysfunction at resting condition or diminished cardiac functional reserve following dobutamine stress echocardiography (DSE).

METHODS AND RESULTS: A total of 66 dysmetabolic and diabetic cynomolgus (Macaca fascicularis) NHPs were enrolled to select 19 NHPs (MetS) with marked metabolic disorders and diabetes (fasting blood glucose: 178 ± 18 vs. 61 ± 3 mg/dL) accompanied by proteinuria (ACR: 134 ± 34 vs. 1.5 ± 0.4 mg/mmol) compared to 8 normal NHPs (CTRL). Under resting condition, MetS NHPs showed mild left ventricular (LV) diastolic dysfunction (E/A: 1 ± 0.06 vs. 1.5 ± 0.13), but with preserved ejection fraction (EF: 65 ± 2 vs. 71 ± 3%) compared to CTRL. DSE with an intravenous infusion of dobutamine at ascending doses (5, 10, 20, 30 and 40 μg/kg/min, 7 min for each dose) resulted in a dose-dependent increase in cardiac function, however, with a significantly diminished magnitude at the highest dose of dobutamine infusion (40 μg/kg/min) in both diastole (E/A: -12 ± 3 vs. -38 ± 5%) and systole (EF: 25 ± 3 vs. 33 ± 5%) as well as ~42% reduced cardiac output reserve (COR: 63 ± 8 vs. 105 ± 18%, p < 0.02) in the MetS compared to CTRL NHPs.

CONCLUSION: These data demonstrate that MetS NHPs with cardiorenal complications: proteinuria, LV diastolic dysfunction and preserved LV systolic function under resting conditions displayed compromised cardiac functional reserve under dobutamine stress. Based on these phenotypes, this NHP model of diabetes with cardiorenal complications can be used as a highly translational model mimic human disease for pharmaceutical research.

Copyright © 2021 Elsevier Inc. All rights reserved.

Keywords: Cardiorenal dysfunction; Diabetic complications; Dobutamine stress test; Echocardiography; Metabolic syndrome; Monkey model

Conflict of interest statement

Declaration of competing interest All the authors were the employees of AstraZeneca or Crown Bioscience Inc. and declare no conflict of interests in this study.

Publication Types